全文获取类型
收费全文 | 1461407篇 |
免费 | 117374篇 |
国内免费 | 5007篇 |
专业分类
耳鼻咽喉 | 18809篇 |
儿科学 | 47558篇 |
妇产科学 | 42089篇 |
基础医学 | 206111篇 |
口腔科学 | 38740篇 |
临床医学 | 131855篇 |
内科学 | 293844篇 |
皮肤病学 | 34356篇 |
神经病学 | 119688篇 |
特种医学 | 54941篇 |
外国民族医学 | 470篇 |
外科学 | 215850篇 |
综合类 | 38905篇 |
现状与发展 | 5篇 |
一般理论 | 495篇 |
预防医学 | 114492篇 |
眼科学 | 32660篇 |
药学 | 103247篇 |
54篇 | |
中国医学 | 5627篇 |
肿瘤学 | 83992篇 |
出版年
2021年 | 13376篇 |
2019年 | 13354篇 |
2018年 | 18403篇 |
2017年 | 14327篇 |
2016年 | 15637篇 |
2015年 | 18056篇 |
2014年 | 25261篇 |
2013年 | 36519篇 |
2012年 | 49980篇 |
2011年 | 52606篇 |
2010年 | 31371篇 |
2009年 | 29818篇 |
2008年 | 47585篇 |
2007年 | 50009篇 |
2006年 | 50133篇 |
2005年 | 48320篇 |
2004年 | 45631篇 |
2003年 | 43498篇 |
2002年 | 41657篇 |
2001年 | 73408篇 |
2000年 | 74845篇 |
1999年 | 61826篇 |
1998年 | 17233篇 |
1997年 | 15644篇 |
1996年 | 15779篇 |
1995年 | 14945篇 |
1994年 | 13527篇 |
1993年 | 12677篇 |
1992年 | 45927篇 |
1991年 | 43537篇 |
1990年 | 41548篇 |
1989年 | 39603篇 |
1988年 | 36232篇 |
1987年 | 35395篇 |
1986年 | 32907篇 |
1985年 | 31316篇 |
1984年 | 23860篇 |
1983年 | 20058篇 |
1982年 | 12255篇 |
1981年 | 10837篇 |
1979年 | 20737篇 |
1978年 | 14595篇 |
1977年 | 12113篇 |
1976年 | 11393篇 |
1975年 | 11637篇 |
1974年 | 14000篇 |
1973年 | 13547篇 |
1972年 | 12642篇 |
1971年 | 11477篇 |
1970年 | 10916篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
72.
73.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献74.
Toidi Adekambi Chris C. Ibegbu Stephanie Cagle Ameeta S. Kalokhe Yun F. Wang Yijuan Hu Cheryl L. Day Susan M. Ray Jyothi Rengarajan 《The Journal of clinical investigation》2015,125(5):1827-1838
BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient’s sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.METHODS. Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.RESULTS. Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.CONCLUSION. We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure.TRIAL REGISTRATION. Registration is not required for observational studies.FUNDING. This study was funded by Emory University, the NIH, and the Yerkes National Primate Center. 相似文献
75.
目的:探讨美托洛尔(β1受体阻滞剂)用于老年COPD合并冠心病史治疗的临床疗效。方法:选取2018年6月—2019年6月在我院接受治疗的60岁以上(包括60岁)COPD合并冠心病史老年患者,分为对照组与观察组。对照组给予接受布地奈德福莫特罗粉吸入剂治疗,观察组在使用布地奈德福莫特罗粉吸入剂治疗的基础上口服琥珀酸美托洛尔缓释片治疗,观察对比两组治疗效果。结果:观察组临床治疗效果优于对照组,观察组住院时长以及并发症的发生率低于对照组(P<0.05),差异具有统计学意义。结论:老年COPD合并冠心病史接受美托洛尔治疗,可有效缩短住院时长、用药效果明显、有效提升用药安全性,值得临床推广。 相似文献
76.
C. Lindsay DeVane 《Pharmacotherapy》2016,36(9):953-954
77.
78.
79.